Skip to content
Quebec News Tribune – Lifestyle
Author:
Entera Bio Ltd.
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
June 16, 2026
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
June 16, 2026
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis – Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
May 28, 2026
←
Previous Page
1
2